---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-017379"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2024-01-29T23:59:59+00:00"
generated_at: "2026-06-06T16:01:33.931905+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics appoints Jason A. Amello as CFO effective Jan 29, 2024

## Summary
- Jason A. Amello appointed CFO effective January 29, 2024; previously CFO at Candel Therapeutics, Akebia, and Saniona.
- Base salary of $500,000 per annum, one-time payment of $60,000, option for 750,000 shares vesting over 4 years.
- Eligible for discretionary bonus target up to 40% of base salary; severance and change-of-control provisions consistent with non-CEO executives.
- Prior interim CFO responsibilities held by CEO Gavin MacBeath and VP Finance Leiden Dworak cease as of Start Date.

## SEC filing metadata
- accession: 0001193125-24-017379
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2024-01-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312524017379/0001193125-24-017379-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312524017379/d683269d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-017379
- JSON: https://secwatch.observer/filing/0001193125-24-017379.json
- Plain text: https://secwatch.observer/filing/0001193125-24-017379.txt

## Key facts
- Executive change
  Jason A. Amello was appointed as Chief Financial Officer at TScan Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On January 29, 2024, TScan Therapeutics, Inc. (the “Company”) announced the appointment of Jason A. Amello as Chief Financial Officer, which was approved by the Board of Directors of the Company on January 24, 2024, effective January 29, 2024 (the “Start Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312524017379/0001193125-24-017379-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.